X

Trial Profile

A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 04 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary)
Indications Meningioma
Focus Therapeutic Use

Most Recent Events

08 Jun 2021 Results(n=12) reporting initial experience with pembrolizumab for refractory atypical/anaplastic meningioma (RAM) and HPC patients presented at the 57th Annual Meeting of the American Society of Clinical Oncology
16 Apr 2019 Planned End Date changed from 1 Feb 2021 to 1 Feb 2020.
16 Apr 2019 Planned primary completion date changed from 1 Feb 2019 to 1 Feb 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com